Trial Profile
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2012
Price :
$35
*
At a glance
- Drugs VQW 765 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Apr 2012 Actual patient number 57 added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Feb 2011 Planned end date changed from 1 Feb 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.